Assessing Recursion Pharmaceuticals (RXRX) Valuation After Recent Share Price Weakness And Split Fair Value Views

Event driven snapshot of Recursion Pharmaceuticals Recursion Pharmaceuticals (RXRX) shares have been drawing attention after ...

Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer

Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodman, M.D., will become Recursion’s Chief Medical Officer ...

Recursion Pharmaceuticals Details AI-Driven Drug Pipeline, Sanofi/Roche Milestones, Runway to 2028

Chief Financial Officer Ben Taylor outlined the company’s integrated approach to AI-enabled drug discovery and development, ...

Recursion names Vicki Goodman as CMO

Recursion (Nasdaq: RXRX) said on Wednesday that it had named Vicki Goodman as chief medical officer, effective April 6, 2026, succeeding David Mauro. Goodman had more than two decades of experience in ...

Want $1 Million in Retirement? Invest $10,000 in These 2 AI Stocks and Hold for 10 Years.

AI is rewriting drug discovery. Recursion Pharmaceuticals and Tempus AI might be the platforms that turn early investors into ...

Jim Cramer on Recursion Pharmaceuticals: “It’s a let down, big let down”

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer answered questions about. When a caller ...
STAT

Recursion CEO: Biotech’s rainy season is not over — but we must race ahead

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...
FierceBiotech

JPM24: Nvidia expands drug discovery footprint with new Amgen, Recursion alliances

Nvidia’s forthright ambitions to expand its drug development footprint are coming into focus, with the global computing powerhouse announcing a trio of new initiatives including a new collaboration ...
Forbes

What's Happening With RXRX Stock?

Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...
The Motley Fool

The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.

Recursion Pharmaceuticals is merging with Exscientia. The new entity will have the backing of quite a few big names in pharma. It'll also have an even more capable drug discovery and development ...

Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and ...
Forbes

Biotech Recursion Pharma Drops Back To IPO Price — Again.

It’s got all the correct buzzwords for a hot biotech stock: machine learning, cell images, artificial intelligence. When Recursion Pharmaceutical went public at $18/share back in April, the stock ...